Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/47390
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gürbüz, Mustafa | - |
dc.contributor.author | Akkuş, Erman | - |
dc.contributor.author | Sakin Abdullah | - |
dc.contributor.author | Urvay, Semiha | - |
dc.contributor.author | Demiray, Atike Gökçen | - |
dc.contributor.author | Şahin, Süleyman | - |
dc.contributor.author | Şakalar, Teoman | - |
dc.contributor.author | Erol, Cihan | - |
dc.contributor.author | Şendur, Mehmet Ali Nahit | - |
dc.contributor.author | Şahin, Ahmet Bilgehan | - |
dc.contributor.author | Çubukçu, Erdem | - |
dc.contributor.author | Güven, Deniz Can | - |
dc.contributor.author | Kılıçkap, Saadettin | - |
dc.contributor.author | Ergün, Yakup | - |
dc.contributor.author | Uncu, Doğan | - |
dc.contributor.author | Turhal, Nazım Serdar | - |
dc.contributor.author | Üskent, Necdet | - |
dc.contributor.author | Çınkır, Havva Yeşil | - |
dc.contributor.author | Demir, Atakan | - |
dc.contributor.author | Acar, Ramazan | - |
dc.contributor.author | Karadurmuş, Nuri | - |
dc.contributor.author | Türker, Sema | - |
dc.contributor.author | Altınbaş, Mustafa | - |
dc.contributor.author | Karaoğlan, Mert | - |
dc.contributor.author | Şenler, Filiz Çay | - |
dc.date.accessioned | 2023-01-09T21:24:18Z | - |
dc.date.available | 2023-01-09T21:24:18Z | - |
dc.date.issued | 2022 | - |
dc.identifier.issn | 1941-6628 | - |
dc.identifier.uri | https://doi.org/10.1007/s12029-021-00594-1 | - |
dc.identifier.uri | https://hdl.handle.net/11499/47390 | - |
dc.description.abstract | Purpose: In the ToGA trial for HER2-positive advanced gastric cancer, cisplatin plus fluoropyrimidine was given for 6 cycles; trastuzumab was given until disease progression. However, there is a lack of real-life data about trastuzumab maintenance after 6 cycle chemotherapy. This study aims to present real-life data of trastuzumab ± capecitabine maintenance after 6 cycles of platinum, fluoropyrimidine, and trastuzumab in non-progressive patients. Methods: This is a retrospective multicenter study of the Turkish Oncology Group. A total of 35 HER2-positive, inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma patients being non-progressive at the end of 6 cycle chemotherapy and being given trastuzumab ± capecitabine as maintenance treatment were included from sixteen oncology centers. Baseline characteristics, objective tumor responses, progression free and overall survival data, and toxicities were determined. Results: About 68% of the patients were given CF, and 32% were given FOLFOX with trastuzumab as the first-line treatment. The best response in 6 cycle chemotherapy was complete 8 (22%), partial 24 (68%), and stable disease 3 (8%). All patients had trastuzumab maintenance (median cycle 13; range 7–51), and 49% of the patients had capecitabine with trastuzumab (median capecitabine cycle 6; range 2–30). The median PFS of the patients was 12.0 months (95% CI 10.3–13.7), and median OS was 17.4 months (95% CI 15.2–19.5). There were 2 patients with grade 1 cardiotoxicity. Conclusion: Trastuzumab maintenance ± capecitabine after 6 cycles of trastuzumab plus combined chemotherapy treatment revealed efficacy and safety in non-progressive HER2-positive advanced gastric cancer. © 2021, Springer Science+Business Media, LLC, part of Springer Nature. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer | en_US |
dc.relation.ispartof | Journal of Gastrointestinal Cancer | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Chemotherapy | en_US |
dc.subject | Gastric cancer | en_US |
dc.subject | HER2 | en_US |
dc.subject | Maintenance | en_US |
dc.subject | Trastuzumab | en_US |
dc.subject | capecitabine | en_US |
dc.subject | cisplatin | en_US |
dc.subject | epidermal growth factor receptor 2 | en_US |
dc.subject | fluorouracil | en_US |
dc.subject | folinic acid | en_US |
dc.subject | oxaliplatin | en_US |
dc.subject | trastuzumab | en_US |
dc.subject | antineoplastic agent | en_US |
dc.subject | capecitabine | en_US |
dc.subject | epidermal growth factor receptor 2 | en_US |
dc.subject | trastuzumab | en_US |
dc.subject | adjuvant chemoradiotherapy | en_US |
dc.subject | adult | en_US |
dc.subject | aged | en_US |
dc.subject | anemia | en_US |
dc.subject | Article | en_US |
dc.subject | bone metastasis | en_US |
dc.subject | cardiotoxicity | en_US |
dc.subject | clinical article | en_US |
dc.subject | colorectal adenocarcinoma | en_US |
dc.subject | diarrhea | en_US |
dc.subject | drug efficacy | en_US |
dc.subject | drug safety | en_US |
dc.subject | fatigue | en_US |
dc.subject | febrile neutropenia | en_US |
dc.subject | female | en_US |
dc.subject | fever | en_US |
dc.subject | hand foot syndrome | en_US |
dc.subject | human | en_US |
dc.subject | infusion related reaction | en_US |
dc.subject | liver metastasis | en_US |
dc.subject | lung metastasis | en_US |
dc.subject | lymph node metastasis | en_US |
dc.subject | maintenance therapy | en_US |
dc.subject | male | en_US |
dc.subject | multiple cycle treatment | en_US |
dc.subject | nausea | en_US |
dc.subject | neoadjuvant chemotherapy | en_US |
dc.subject | neutropenia | en_US |
dc.subject | observational study | en_US |
dc.subject | overall survival | en_US |
dc.subject | peritoneum metastasis | en_US |
dc.subject | progression free survival | en_US |
dc.subject | rash | en_US |
dc.subject | retrospective study | en_US |
dc.subject | stomach adenocarcinoma | en_US |
dc.subject | thrombocytopenia | en_US |
dc.subject | Turkey (republic) | en_US |
dc.subject | vomiting | en_US |
dc.subject | clinical trial | en_US |
dc.subject | multicenter study | en_US |
dc.subject | pathology | en_US |
dc.subject | stomach tumor | en_US |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | en_US |
dc.subject | Capecitabine | en_US |
dc.subject | Humans | en_US |
dc.subject | Receptor, ErbB-2 | en_US |
dc.subject | Retrospective Studies | en_US |
dc.subject | Stomach Neoplasms | en_US |
dc.subject | Trastuzumab | en_US |
dc.title | Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 53 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.startpage | 282 | en_US |
dc.identifier.endpage | 288 | en_US |
dc.identifier.doi | 10.1007/s12029-021-00594-1 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorscopusid | 57217738098 | - |
dc.authorscopusid | 57204653249 | - |
dc.authorscopusid | 55293011200 | - |
dc.authorscopusid | 57191612456 | - |
dc.authorscopusid | 57200169071 | - |
dc.authorscopusid | 56890545900 | - |
dc.authorscopusid | 57204201984 | - |
dc.identifier.pmid | 33538958 | en_US |
dc.identifier.scopus | 2-s2.0-85100518751 | en_US |
dc.identifier.scopusquality | Q3 | - |
item.languageiso639-1 | en | - |
item.openairetype | Article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu |
CORE Recommender
SCOPUSTM
Citations
3
checked on Jun 29, 2024
Page view(s)
44
checked on May 27, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.